Delcath Systems Inc (DCTH)

$9.97 -0.01 (-0.10%)
Market Cap 349.96M
Revenue (ttm) 37.21M
Net Income (ttm) -26.39M
EPS (ttm) N/A
PE Ratio 58.29
Forward PE 17.09
Profit Margin -70.92%
Debt to Equity Ratio 0.00
Volume 914,400
Avg Vol 565,136
Day's Range N/A - N/A
Shares Out 35.31M
Stochastic %K 20%
Beta 0.39
Analysts Strong Sell
Price Target $23.50

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices
Sector: Healthcare
Phone: 212 489 2100
Fax: 212 489 2102
Address:
566 Queensbury Avenue, New York, United States
mar99
mar99 Feb. 4 at 3:05 PM
$DCTH What the heck is going on here? So weak. Recovered all that loss yesterday by the close. Up over 10 this morning and then a modest amount of shares sold and we are even lower than yesterday’s low. Down 35 cents again. Just so weak.
1 · Reply
JFais
JFais Feb. 3 at 11:24 PM
$DCTH- hear you but would still think (at least in some cases) it's a both/and situation for Hepzato Kit & SOC, not either/or
1 · Reply
alexpitti
alexpitti Feb. 3 at 5:15 PM
wtf $DCTH
1 · Reply
mar99
mar99 Feb. 3 at 5:13 PM
$DCTH Dropped 35 cents in 10 minutes. Weird.
1 · Reply
Humdinger1966
Humdinger1966 Feb. 2 at 7:13 PM
$DCTH The FDA has just published (Jan 26) a document titled: "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products" at https://www.fda.gov/media/190505/download. I think that Section III-D is of particular interest to DCTH.
1 · Reply
actuallysam
actuallysam Feb. 2 at 3:17 PM
$DCTH I agree the odds favor stock appreciation for several years including 2026.
0 · Reply
GioW
GioW Feb. 2 at 1:34 PM
$DCTH At the conference call on March they will have a good estimate of what Q1 is looking like. With 28 centres treating at 1.7 treatments per centre from late Jan (Q3 2025 levels) the math would suggest $26M for Q1 including ROW. That’s 26% increaseQoQ and 37% increase YOY for Q1.
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 10:52 PM
$DCTH when you do a repurchase program of up to $25 million and does not have an expiration date. Than you realize this company is an easy double
0 · Reply
JFais
JFais Jan. 31 at 9:39 PM
$DCTH- a good example of having this LT visibility Valued at just 4x 2025 sales. Paid down the debt, buying back shares Pricing pressure for Hepzato & seasonality = near-term noise & nothing more Practice-changing results from CHOPIN to accelerate uptake in docs who don't want to postpone systemic treatment/ICI Expanding into other solid tumors with liver involvement, starting with breast & CRC. Steady stream of data once you hit 2027 (interim CRC then breast), primary CRC readout in 2028 & primary breast readout in 2029 (full OS in 2030). Additional indications to be pursued as sales ramp & funding obtained (ICC, melanoma, NSCLC, etc)
1 · Reply
GioW
GioW Jan. 31 at 10:10 AM
$DCTH with MD Anderson and Mayo clinic now treating and, as previously mentioned, MSK (added in Oct) this massively increases visibility. Portland is in set up which would give a treating centre in the Northwest. Geographically that’s important so I’d predict that’s next to register as active. Atlanta would be a good addition but it’s been on the kit site but not REMS forever.
1 · Reply
Latest News on DCTH
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 27, 2026, 8:05 AM EST - 8 days ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 21, 2026, 4:01 PM EST - 13 days ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Jan 13, 2026, 12:22 PM EST - 21 days ago

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 9, 2026, 8:05 AM EST - 26 days ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 31, 2025, 8:00 AM EST - 5 weeks ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 2 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 20, 2025, 4:01 PM EST - 2 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 18, 2025, 8:00 AM EST - 2 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 13, 2025, 8:30 AM EST - 2 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:01 PM EST - 3 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath: Temporary Headwinds Are No Cause For Concern

Nov 6, 2025, 2:15 PM EST - 3 months ago

Delcath: Temporary Headwinds Are No Cause For Concern

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:16 PM EST - 3 months ago

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Nov 4, 2025, 8:00 AM EST - 3 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Oct 20, 2025, 5:05 PM EDT - 3 months ago

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Delcath: Large Upside With Limited Downside Risk

Oct 20, 2025, 3:06 PM EDT - 3 months ago

Delcath: Large Upside With Limited Downside Risk

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:15 PM EDT - 3 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Oct 18, 2025, 4:13 PM EDT - 3 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 22, 2025, 4:01 PM EDT - 4 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 19, 2025, 8:30 AM EDT - 6 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:06 PM EDT - 6 months ago

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Aug 6, 2025, 8:00 AM EDT - 6 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:01 PM EDT - 6 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jul 23, 2025, 4:01 PM EDT - 6 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Delcath Systems: Growing Fast, But Business Model Is Fragile

Jun 12, 2025, 8:36 AM EDT - 8 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025, 7:00 AM EDT - 9 months ago

Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 18, 2025, 8:25 AM EDT - 9 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025, 4:30 PM EDT - 9 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 5:30 PM EDT - 9 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:55 AM EDT - 9 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025, 7:30 AM EDT - 9 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 24, 2025, 4:01 PM EDT - 10 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 9, 2025, 5:00 PM EDT - 10 months ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Apr 2, 2025, 11:49 AM EDT - 11 months ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 24, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 14, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 2:17 PM EST - 11 months ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Mar 6, 2025, 8:00 AM EST - 11 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Begins Platform Expansion With Two Phase 2 Trials

Nov 20, 2024, 7:50 AM EST - 1 year ago

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Nov 18, 2024, 7:09 AM EST - 1 year ago

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 12:30 PM EST - 1 year ago

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

mar99
mar99 Feb. 4 at 3:05 PM
$DCTH What the heck is going on here? So weak. Recovered all that loss yesterday by the close. Up over 10 this morning and then a modest amount of shares sold and we are even lower than yesterday’s low. Down 35 cents again. Just so weak.
1 · Reply
JFais
JFais Feb. 3 at 11:24 PM
$DCTH- hear you but would still think (at least in some cases) it's a both/and situation for Hepzato Kit & SOC, not either/or
1 · Reply
alexpitti
alexpitti Feb. 3 at 5:15 PM
wtf $DCTH
1 · Reply
mar99
mar99 Feb. 3 at 5:13 PM
$DCTH Dropped 35 cents in 10 minutes. Weird.
1 · Reply
Humdinger1966
Humdinger1966 Feb. 2 at 7:13 PM
$DCTH The FDA has just published (Jan 26) a document titled: "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products" at https://www.fda.gov/media/190505/download. I think that Section III-D is of particular interest to DCTH.
1 · Reply
actuallysam
actuallysam Feb. 2 at 3:17 PM
$DCTH I agree the odds favor stock appreciation for several years including 2026.
0 · Reply
GioW
GioW Feb. 2 at 1:34 PM
$DCTH At the conference call on March they will have a good estimate of what Q1 is looking like. With 28 centres treating at 1.7 treatments per centre from late Jan (Q3 2025 levels) the math would suggest $26M for Q1 including ROW. That’s 26% increaseQoQ and 37% increase YOY for Q1.
0 · Reply
scotttrader213
scotttrader213 Jan. 31 at 10:52 PM
$DCTH when you do a repurchase program of up to $25 million and does not have an expiration date. Than you realize this company is an easy double
0 · Reply
JFais
JFais Jan. 31 at 9:39 PM
$DCTH- a good example of having this LT visibility Valued at just 4x 2025 sales. Paid down the debt, buying back shares Pricing pressure for Hepzato & seasonality = near-term noise & nothing more Practice-changing results from CHOPIN to accelerate uptake in docs who don't want to postpone systemic treatment/ICI Expanding into other solid tumors with liver involvement, starting with breast & CRC. Steady stream of data once you hit 2027 (interim CRC then breast), primary CRC readout in 2028 & primary breast readout in 2029 (full OS in 2030). Additional indications to be pursued as sales ramp & funding obtained (ICC, melanoma, NSCLC, etc)
1 · Reply
GioW
GioW Jan. 31 at 10:10 AM
$DCTH with MD Anderson and Mayo clinic now treating and, as previously mentioned, MSK (added in Oct) this massively increases visibility. Portland is in set up which would give a treating centre in the Northwest. Geographically that’s important so I’d predict that’s next to register as active. Atlanta would be a good addition but it’s been on the kit site but not REMS forever.
1 · Reply
GioW
GioW Jan. 31 at 9:59 AM
$DCTH I think the jump to over 11 and subsequent dumping was a pump and dump. It’s classical manipulation of microcap stocks with small float.
0 · Reply
SouthernCharm
SouthernCharm Jan. 30 at 3:42 PM
$DCTH not a good look today. is it time to start tracking put options again?
0 · Reply
xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Jan. 29 at 8:55 PM
$DCTH had to buy more... I am going bankrupt soon with Delcath. But cannot help as the company keeps executing and future looks bright.
3 · Reply
brunoq14
brunoq14 Jan. 29 at 6:42 PM
$DCTH M.D. Anderson and Sloan-Kettering, which have both joined the Delcath network recently, are considered by many the top two cancer centers in the world.
0 · Reply
actuallysam
actuallysam Jan. 29 at 6:12 PM
$DCTH Academic hospitals also train medical personnel, so it is complicated trying to assess the path to acceptance by the medical community.
0 · Reply
actuallysam
actuallysam Jan. 29 at 5:30 PM
$DCTH With 2 sites close by in Texas and 2 sites close by in Arizona, maybe this summer will be less seasonal.
1 · Reply
RemitTekram
RemitTekram Jan. 29 at 5:22 PM
$DCTH Going to give this another try here. Stop wasting our time and decide which way you’re going to go.
0 · Reply
mar99
mar99 Jan. 29 at 4:56 PM
$DCTH Nice to see MD Anderson on board now.
0 · Reply
alexpitti
alexpitti Jan. 29 at 4:35 PM
$DCTH added 28th center
1 · Reply
mar99
mar99 Jan. 28 at 9:11 PM
$DCTH Not sure why we are so weak since the run up to 11 a few days ago. Pretty consistent selling in this ugly take down. I didn’t think we’d see below 10 again after Chopin and with the company buying back shares. I clearly was wrong. Picked up a little more today including a small purchase after hours at 9.8999. Very surprised with this drop for no reason.
1 · Reply
forprofit12
forprofit12 Jan. 27 at 9:37 PM
$DCTH not sure which of the two scenarios happens first, hell freezes or this goes up to 18. What a complete beatdown after posting great trial results.
1 · Reply
mar99
mar99 Jan. 27 at 8:44 PM
$DCTH You have to love a near 5% takedown for no reason. Stock looked good a few days ago with that move over 11. Now we are back to the regular game playing, manipulation, algos, walk downs, etc. Someday it will go up and stay up. Apparently not yet.
1 · Reply